The PBS in a globalised world: free trade and reference pricing

Australian Health Review

Volumn 33, Issue 2, 2009, Pages 186-191

  Searles, Andrew ^a  

^a UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 66749188629     PISSN: 01565788     EISSN: 14498944     Source Type: Journal    
DOI: 10.1071/AH090186     Document Type: Article

References (27)

1. Faunce TA. Reference pricing for pharmaceuticals: is the Australia-United States Free Trade Agreement affecting Australia's Pharmaceutical Benefits Scheme? Med J Aust 2007; 187: 240-2. Epub 2007 Jun 13.
2. Searles A, Jefferys S, Doran E, Henry DA. Reference pricing, generic drugs and proposed changes to the Pharmaceutical Benefits Scheme. Med J Aust 2007; 187: 236-9. Epub 2007 Jun 13.
3. Australian Government Department of Foreign Affairs and Trade. Free trade agreements [webpage]. 2008. Available at: http://www.dfat.gov.au/trade/ftas.html (cited 18 Feb 2009).
4. Centre for International Economics. Economic analysis of AUSFTA: Impact of the bilateral free trade agreement with the United States. (Prepared for the Department of Foreign Affairs and Trade.) Canberra: CIE, 2004.
5. Siriwardana M. The Australia-United States Free Trade Agreement: an economic evaluation. North American Journal of Economics and Finance 2007; 18 (1): 117-33.
6. Senator Kay Patterson. Hansard: Community Affairs Legislation Committee. 2 June, 2003: CAA 111.
7. The Honourable John Howard. Hansard, 12 August 2004. Parliament of Australia: 32938.
8. Business Council of Australia. Business Council of Australia Submission on Australia US Free Trade Agreement (AUSFTA) to Joint Standing Committee on Treaties [webpage]. 2004. www.bca.com.au (cited 19 Aug 2005).
9. Burton K, Varghese J. The PBS and the Australia-US Free Trade Agreement. Research Note 2004-05 No. 3, 21 July 2004. Parliamentary Library. Available at: http://www.aph.gov.au/library/pubs/rn/2004-05/05rn03.pdf
10. Denniss R, Hamilton C. Submission 171 to the Senate Select Committee on the Free Trade Agreement between Australia and the United States of America [web-based submission]. The Australia Institute, 2004. Available at: http://www.aph.gov.au/senate/committee/freetrade_ctte/submissions/sub171.pdf (cited 1 Feb 2009).
11. Drahos P, Lukuge B, Goddard M, Henry D. Pharmaceuticals, intellectual property and free trade: the case of the US-Australia Free Trade Agreement. Prometheus 2004; 22 (3): 243-57.
12. The Office of the United States Trade Representative. US-Australia Free Trade Agreement - questions and answers about pharmaceuticals. 7 Aug 2004. Available at: http://www.ustr.gov/Document_Library/Fact_Sheets/2004/US-Australia_Free_Trade_Agreement_--_Questions_Answers_About_Pharmaceuticals.html (cited 12 Sep 2008).
13. United States: Trade Act of 2002. Public Law 107-210 2002.
14. Australian Government Productivity Commission. International pharmaceutical price differences. Canberra: PC, 2001.
15. US Department of Commerce International Trade Administration. Pharmaceutical price controls in OECD countries: implications for US consumers, pricing, research and development, and innovation. Washington, DC: Dec 2004.
16. Outterson K. Agony in the Antipodes: the generic drug provisions of the Australia-US Free Trade Agreement. Journal of Generic Medicines 2005; 2 (4): 316-26.
17. Shiner JS. Testimony of Deputy US Trade Representative Jossette Sheeran Shiner before the Committee on Finance Subcommittees on Health Care and International Trade. Washington: United States Senate, 2004.
18. Commonwealth of Australia. Australia-United States Free Trade Agreement. 2004. Available at: http://www.austrade.gov.au/default.aspx?ArticleID=8310#AUSFTA (cited 17 Sep 2008).
19. Mercurio B. The impact of the Australia-United States Free Trade Agreement on the provision of health services in Australia. Whittier Law Review 2005; 26: 1051-100.
20. Commonwealth of Australia Senate Committee. Senate Committee Report: Select Committee on the Free Trade Agreement between Australia and the United States of America. Canberra: Parliament of Australia, 2004.
21. Faunce TA, Shats K. Bilateral trade agreements as drivers of national and transnational benefit from health technology policy: implications of recent US deal for Australia negotiations with China and India. Australian Journal of International Affairs 2008; 62 (2): 196-213.
22. Laming A. Let's overhaul the Pharmaceutical Benefits Scheme. The Australian 2006; 10 Jan: 10.
23. Pharma in Focus. Pain worth the gain in PBS reform. Pharma in Focus 27 Nov-3 Dec 2006.
24. Abbott T. PBS reform [media release ABB 152/06]. 16 Nov 2006. Available at: http://www.health.gov.au/internet/ministers/publishing.nsf/Content/01E0717C1E86B7CACA2572270081C67A/$File/abb152.pdf
25. Department of Health and Ageing. Formulary allocations January 2009. http://www.health.gov.au/internet/main/publishing.nsf/Content/B631AE281B89C9D7CA2572AB0005EE96/$File/Formularies%20-%201%20January%2009%20-%20FINAL.pdf (cited 13 Jan 2009).
26. Lopert R, Rosenbaum S. What is fair? Choice, fairness, and transparency in access to prescription medicines in the United States and Australia. Journal of Law, Medicine & Ethics 2007; 35 (4): 643-56.
27. Australian Government Department of Health and Ageing, Medicines Australia. The Access to Medicines Working Group Interim Report to Government. Canberra: 2008.